enGene Therapeutics Inc. (ENGN)
Nasdaq: ENGN · Biological Products, (No Diagnostic Substances) · Saint-Laurent, QC · filing with the SEC since 2023
Who runs enGene Therapeutics Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Cooper Ronald Harold Wilfred
CEO & President. First filing Jul 2024, latest Feb 3, 2026, 1 filing in all.
Officers reporting now
12
of 19 people with a filing in the last fifteen months
Directors reporting now
7
26 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Grossman William | Interim Chief Medical Officer | Jul 2025 | Sep 24, 2026 | none |
| Chinoporos Constantine | Interim Chief Business Officer | Jul 2026 | Jul 22, 2026 | none |
| Richton Kathleen P. | SVP, Finance and Treasurer | Jul 2026 | Jul 22, 2026 | none |
| Cooper Ronald Harold Wilfred | CEO & President | Jul 2024 | Feb 3, 2026 | none |
| Daws D. Ryan | Chief Financial Officer | Nov 2023 | Feb 3, 2026 | none |
| Boyd Matthew Ross | Chief Regulatory Officer | Jul 2025 | Feb 3, 2026 | none |
| Buck Jill | Chief Development Officer | Jul 2025 | Feb 3, 2026 | none |
| Cheung Anthony Tzeyew | Chief Scientific Officer | Oct 2023 | Feb 3, 2026 | none |
| Connolly Joan | Chief Technology Officer | Oct 2024 | Feb 3, 2026 | none |
| Giguere Lee | Chief Legal Ofc. and Corp Secy | Feb 2024 | Feb 3, 2026 | none |
| Nichols Alexander Julian | Chief Strategy & Ops. Ofc | Oct 2023 | Feb 3, 2026 | none |
| Sweiti Hussein | Chief Medical Officer | Oct 2025 | Oct 1, 2025 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Astley-Sparke Philip | director | Jul 2025 | Jun 17, 2026 | none |
| Brunk Gerald A | director | Oct 2023 | Jun 17, 2026 | none |
| Glickman Richard M | director | Oct 2023 | Jun 17, 2026 | none |
| Hastings Paul J | director | May 2024 | Jun 17, 2026 | none |
| Heffernan Michael Thomas | director | Jul 2025 | Jun 17, 2026 | none |
| Joustra Wouter | director | May 2024 | Jun 17, 2026 | none |
| Zoth Lota S. | director | Dec 2023 | Jun 17, 2026 | none |
Earlier names on the record24, newest filing first
Pott Amy · officer · last filing Jun 2025Bos Jasper · director · last filing Jun 2025Pruthi Raj Som · officer · last filing Jan 2025Forbion Growth Management B.V. · 10% owner · last filing Nov 2024Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner · last filing Nov 2024Fonds De Solidarite Des Travailleurs Du Quebec · 10% owner · last filing Apr 2024Lumira Capital Investment Management Inc. · 10% owner · last filing Feb 2024Bryce Richard Paul · officer · last filing Dec 2023Biotechnology Value Fund II LP · other · last filing Nov 2023Biotechnology Value Fund L P · other · last filing Nov 2023Biotechnology Value Trading Fund Os LP · other · last filing Nov 2023Bvf Gp Holdings LLC · 10% owner · last filing Nov 2023Bvf I Gp LLC · other · last filing Nov 2023Bvf II Gp LLC · other · last filing Nov 2023Bvf Inc/il · 10% owner · last filing Nov 2023Bvf Partners L P/il · 10% owner · last filing Nov 2023Bvf Partners Os Ltd. · other · last filing Nov 2023Forbion Capital Fund III Cooperatief U.A. · 10% owner · last filing Nov 2023Forbion III Management B.V. · 10% owner · last filing Nov 2023Lampert Mark N · 10% owner · last filing Nov 2023Hanson Jason David · officer · last filing Nov 2023Sullivan James Crowley · officer · last filing Nov 2023Forbion Growth Sponsor Feac I B.V. · 10% owner · last filing Nov 2023Grassin Alexandre Jean-Rene Erwan · officer · last filing Oct 2023
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.